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Background
Inter individual variability to Clopidogrel response is well
recognized as a strapping barrier in front of clinicians. It
has been mentioned that the pharmacogenetic variations
may explain 30-50 percent in this variability [1,2]. Several
recent landmark studies have proven the importance of
2C19 genotyping in treatment using clopidogrel [1-3].
Therefore we sought to investigate the variability in PFT
response to CYP2C19 polymorphism and compare it with
the clinical presentation. Furthermore, cost analysis is
considered.
Materials and methods
One hundred and seventy Saudi patients who were stable
on 75 mg clopidogrel at least for one month for various
cardiac indications were enrolled in Prince Sultan Cardiac
Center, Buraidah. DNA was extracted by MagNAPure
[LC,Roche, Germany].CYP2C19 Genotyping for *1, *2 and
*3 was conducted by real-time PCR [Roche Molecular Bio-
chemicals, Mannheim, Germany]. PFT was carried out by
(Verify Now P2Y12) for all the patients. The clinical events
were documented retrospectively for all patients.
Results
One hundred seventeen patients presented with the wild
variant 1/1, 19 patients with 1/2, and 34 patients with 2/2.
We couldn’t detect allele 3. There is a significant associa-
tion between different genotyping and the percentage of
inhibition (P = 0.0002). 1/1 patients tend to be moderate
to - extensive metabolizers, whereas the majority of the
rest are slow metabolizers. One hundred twenty three
patients presented with no symptoms. Interestingly, no
association was found between the adequacy of the PFT
and the clinical symptoms (P = 0.60) and PPIs did not
affect the overall response. Furthermore, Aspirin dose
didn’t impact on the clinical symptoms (P = 0.080). The
cost of doing the PFT is 250 SR/patient and 200 SR/
patient (real-time PCR) for kits and materials excluding
equipment and labors.
Conclusions
Although the platelet function testing varied significantly
with polymorphism, the clinical symptoms were not asso-
ciated. The running cost is affordable if clinical association
was found to be significant.
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